These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 26577580)

  • 1. Prediagnostic serum glucose and lipids in relation to survival in breast cancer patients: a competing risk analysis.
    Wulaningsih W; Vahdaninia M; Rowley M; Holmberg L; Garmo H; Malmstrom H; Lambe M; Hammar N; Walldius G; Jungner I; Coolen AC; Van Hemelrijck M
    BMC Cancer; 2015 Nov; 15():913. PubMed ID: 26577580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum lipids and outcome of early-stage breast cancer: results of a prospective cohort study.
    Bahl M; Ennis M; Tannock IF; Hux JE; Pritchard KI; Koo J; Goodwin PJ
    Breast Cancer Res Treat; 2005 Nov; 94(2):135-44. PubMed ID: 16261412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes.
    Lofterød T; Mortensen ES; Nalwoga H; Wilsgaard T; Frydenberg H; Risberg T; Eggen AE; McTiernan A; Aziz S; Wist EA; Stensvold A; Reitan JB; Akslen LA; Thune I
    BMC Cancer; 2018 Jun; 18(1):654. PubMed ID: 29902993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The BMP inhibitor DAND5 in serum predicts poor survival in breast cancer.
    Chi Y; Yao L; Hu X; Huang S; Huang N; Li S; Shao Z; Wu J
    Oncotarget; 2016 Mar; 7(12):14951-62. PubMed ID: 26908452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucose and lipoprotein biomarkers and breast cancer severity using data from the Swedish AMORIS cohort.
    Melvin JC; Garmo H; Holmberg L; Hammar N; Walldius G; Jungner I; Lambe M; Van Hemelrijck M
    BMC Cancer; 2017 Apr; 17(1):246. PubMed ID: 28376727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between menopausal hormone therapy and mortality after breast cancer The MARIEplus study, a prospective case cohort.
    Obi N; Heinz J; Seibold P; Vrieling A; Rudolph A; Chang-Claude J; Berger J; Flesch-Janys D
    Int J Cancer; 2016 May; 138(9):2098-108. PubMed ID: 26649645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediagnostic serum inflammatory markers in relation to breast cancer risk, severity at diagnosis and survival in breast cancer patients.
    Wulaningsih W; Holmberg L; Garmo H; Malmstrom H; Lambe M; Hammar N; Walldius G; Jungner I; Van Hemelrijck M
    Carcinogenesis; 2015 Oct; 36(10):1121-8. PubMed ID: 26130675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum glucose, triglycerides, and cholesterol in relation to prostate cancer death in the Swedish AMORIS study.
    Arthur R; Møller H; Garmo H; Häggström C; Holmberg L; Stattin P; Malmström H; Lambe M; Hammar N; Walldius G; Robinson D; Jungner I; Van Hemelrijck M
    Cancer Causes Control; 2019 Feb; 30(2):195-206. PubMed ID: 30421156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fasting blood glucose and long-term prognosis of non-metastatic breast cancer: a cohort study.
    Contiero P; Berrino F; Tagliabue G; Mastroianni A; Di Mauro MG; Fabiano S; Annulli M; Muti P
    Breast Cancer Res Treat; 2013 Apr; 138(3):951-9. PubMed ID: 23568483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma carotenoids and recurrence-free survival in women with a history of breast cancer.
    Rock CL; Flatt SW; Natarajan L; Thomson CA; Bardwell WA; Newman VA; Hollenbach KA; Jones L; Caan BJ; Pierce JP
    J Clin Oncol; 2005 Sep; 23(27):6631-8. PubMed ID: 16170170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations between serum lipids and causes of mortality in a cohort of 3,499 urban Thais: The Electricity Generating Authority of Thailand (EGAT) study.
    Sritara P; Patoomanunt P; Woodward M; Narksawat K; Tulyadachanon S; Ratanachaiwong W; Sritara C; Barzi F; Yamwong S; Tanomsup S
    Angiology; 2007 Dec-2008 Jan; 58(6):757-63. PubMed ID: 18216384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
    Martín M; Ruiz A; Ruiz Borrego M; Barnadas A; González S; Calvo L; Margelí Vila M; Antón A; Rodríguez-Lescure A; Seguí-Palmer MA; Muñoz-Mateu M; Dorca Ribugent J; López-Vega JM; Jara C; Espinosa E; Mendiola Fernández C; Andrés R; Ribelles N; Plazaola A; Sánchez-Rovira P; Salvador Bofill J; Crespo C; Carabantes FJ; Servitja S; Chacón JI; Rodríguez CA; Hernando B; Álvarez I; Carrasco E; Lluch A
    J Clin Oncol; 2013 Jul; 31(20):2593-9. PubMed ID: 23733779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression of breast cancer following locoregional ipsilateral recurrence: importance of interval time.
    Melvin JC; Purushotham AD; Garmo H; Pinder SE; Fentiman IS; Gillett C; Mera A; Lüchtenborg M; Holmberg L; Van Hemelrijck M
    Br J Cancer; 2016 Jan; 114(1):88-95. PubMed ID: 26657655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of bladder cancer by disease severity in relation to metabolic factors and smoking: A prospective pooled cohort study of 800,000 men and women.
    Teleka S; Häggström C; Nagel G; Bjørge T; Manjer J; Ulmer H; Liedberg F; Ghaderi S; Lang A; Jonsson H; Jahnson S; Orho-Melander M; Tretli S; Stattin P; Stocks T
    Int J Cancer; 2018 Dec; 143(12):3071-3082. PubMed ID: 29756343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Risk of cardiovascular death in relation to blood lipid composition in male inhabitants of Tyumen: results of a 12-year prospective study].
    Akimova EV; Gakova EI; Pushkarev GS; Smaznov VIu; Kaiumova MM; Gafarov VV; Kuznetsov VA
    Ter Arkh; 2012; 84(9):41-6. PubMed ID: 23091852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of alterations in plasma lipid profile levels in breast cancer.
    Franky Dhaval Shah ; Shilin Nandubhai Shukla ; Pankaj Manubhai Shah ; Patel HR; Prabhudas Shankerbhai Patel
    Integr Cancer Ther; 2008 Mar; 7(1):33-41. PubMed ID: 18292593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postdiagnosis social networks and breast cancer mortality in the After Breast Cancer Pooling Project.
    Kroenke CH; Michael YL; Poole EM; Kwan ML; Nechuta S; Leas E; Caan BJ; Pierce J; Shu XO; Zheng Y; Chen WY
    Cancer; 2017 Apr; 123(7):1228-1237. PubMed ID: 27943274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cause-specific mortality after a breast cancer diagnosis: a cohort study of 10,195 women in Girona and Tarragona.
    Ameijide A; Clèries R; Carulla M; Buxó M; Marcos-Gragera R; Martínez JM; Vilardell ML; Vilardell M; Espinàs JA; Borràs JM; Izquierdo Á; Galceran J
    Clin Transl Oncol; 2019 Aug; 21(8):1014-1025. PubMed ID: 30607790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between prediagnostic glucose, triglycerides, cholesterol and meningioma, and reverse causality.
    Bernardo BM; Orellana RC; Weisband YL; Hammar N; Walldius G; Malmstrom H; Ahlbom A; Feychting M; Schwartzbaum J
    Br J Cancer; 2016 Jun; 115(1):108-14. PubMed ID: 27253176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a,b) - results from the Munich Cancer Registry.
    Kolben T; Harbeck N; Wuerstlein R; Schubert-Fritschle G; Bauerfeind I; Schrodi S; Engel J
    Breast; 2015 Feb; 24(1):24-31. PubMed ID: 25543874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.